Literature DB >> 11875759

Protean PTEN: form and function.

Kristin A Waite1, Charis Eng.   

Abstract

Germline mutations distributed across the PTEN tumor-suppressor gene have been found to result in a wide spectrum of phenotypic features. Originally shown to be a major susceptibility gene for both Cowden syndrome (CS), which is characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial cancers, and Bannayan-Riley-Ruvalcaba syndrome, which is characterized by lipomatosis, macrocephaly, and speckled penis, the PTEN hamartoma tumor syndrome spectrum has broadened to include Proteus syndrome and Proteus-like syndromes. Exon 5, which encodes the core motif, is a hotspot for mutations likely due to the biology of the protein. PTEN is a major lipid 3-phosphatase, which signals down the PI3 kinase/AKT pro-apoptotic pathway. Furthermore, PTEN is a protein phosphatase, with the ability to dephosphorylate both serine and threonine residues. The protein-phosphatase activity has also been shown to regulate various cell-survival pathways, such as the mitogen-activated kinase (MAPK) pathway. Although it is well established that PTEN's lipid-phosphatase activity, via the PI3K/AKT pathway, mediates growth suppression, there is accumulating evidence that the protein-phosphatase/MAPK pathway is equally important in the mediation of growth arrest and other crucial cellular functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875759      PMCID: PMC379112          DOI: 10.1086/340026

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  114 in total

Review 1.  Protein modules as organizers of membrane structure.

Authors:  A S Fanning; J M Anderson
Journal:  Curr Opin Cell Biol       Date:  1999-08       Impact factor: 8.382

Review 2.  Cowden disease. Report of a family and review.

Authors:  M Longy; D Lacombe
Journal:  Ann Genet       Date:  1996

3.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

4.  PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

Authors:  D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

5.  Localization of the gene for Cowden disease to chromosome 10q22-23.

Authors:  M R Nelen; G W Padberg; E A Peeters; A Y Lin; B van den Helm; R R Frants; V Coulon; A M Goldstein; M M van Reen; D F Easton; R A Eeles; S Hodgsen; J J Mulvihill; V A Murday; M A Tucker; E C Mariman; T M Starink; B A Ponder; H H Ropers; H Kremer; M Longy; C Eng
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

6.  Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis.

Authors:  A Hemminki; I Tomlinson; D Markie; H Järvinen; P Sistonen; A M Björkqvist; S Knuutila; R Salovaara; W Bodmer; D Shibata; A de la Chapelle; L A Aaltonen
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

7.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

8.  Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus.

Authors:  A Metjian; R L Roll; A D Ma; C S Abrams
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

9.  The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.

Authors:  M M Georgescu; K H Kirsch; T Akagi; T Shishido; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

10.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

View more
  125 in total

1.  Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

Authors:  Margaret Sperow; Raymond B Berry; Ildar T Bayazitov; Guo Zhu; Suzanne J Baker; Stanislav S Zakharenko
Journal:  J Physiol       Date:  2011-12-06       Impact factor: 5.182

Review 2.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

3.  Cowden syndrome: mucocutaneous lesions as precursors of internal malignancy.

Authors:  Panagiotis Stathopoulos; Anna Raymond; Michael Esson
Journal:  Oral Maxillofac Surg       Date:  2014-04-01

4.  Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines.

Authors:  Dong-Zhu Ma; Zhen Xu; Yu-Long Liang; Jian-Ming Su; Zeng-Xia Li; Wen Zhang; Li-Ying Wang; Xi-Liang Zha
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

5.  Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs.

Authors:  Anabel Gil; Amparo Andrés-Pons; Elena Fernández; Miguel Valiente; Josema Torres; Javier Cervera; Rafael Pulido
Journal:  Mol Biol Cell       Date:  2006-06-28       Impact factor: 4.138

Review 6.  Of mice and Myc: c-Myc and mammary tumorigenesis.

Authors:  M Hunter Jamerson; Michael D Johnson; Robert B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway.

Authors:  Xuyan Chen; Zhiming Huang; Renpin Chen
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

8.  Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.

Authors:  George McConnachie; Ian Pass; Steven M Walker; C Peter Downes
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

Review 9.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

10.  Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.

Authors:  Xiao-Ping Zhou; Kristin A Waite; Robert Pilarski; Heather Hampel; Magali J Fernandez; Cindy Bos; Majed Dasouki; Gerald L Feldman; Lois A Greenberg; Jennifer Ivanovich; Ellen Matloff; Annette Patterson; Mary Ella Pierpont; Donna Russo; Najah T Nassif; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.